Utama › Osteosarkoma › North Carolina
Kajian klinikal Osteosarkoma di North Carolina
6 kajian untuk Osteosarkoma sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
- Duke University Medical Center, Durham
Mengambil pesertaFasa 2
Umur 12 hingga 39 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT04616560The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
- University of North Carolina at Chapel Hill, Chapel Hill
- Atrium Health Levine Children's Hospital, Charlotte
- Novant Health Hemby Children's Hospital, Charlotte
- dan 3 lagi
Mengambil pesertaFasa 2
Umur 7 hingga 22 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07560826Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
- Mission Hospital, Asheville
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Duke University Medical Center, Durham
- dan 2 lagi
Mengambil pesertaFasa 3
Sehingga umur 50 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT05235165SPEARHEAD-3 Pediatric Study
- Duke University School of Medicine, Durham
Mengambil pesertaFasa 1/2
Umur 2 hingga 21 · Semua jantina · Dikemas kini 11 Ogo 2026 · NCT05642455Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Mission Hospital, Asheville
- Wake Forest University Health Sciences, Winston-Salem
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
Mengambil pesertaFasa 1
18 Months · Semua jantina · Dikemas kini 27 Mac 2026 · NCT03721068Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.